A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 90
- Population
- ALL · 50 Years to 75 Years
- Duration
- 2026-06-01 to 2028-06-01
- Intervention
- EG-301; AREDS2 supplements
- Comparator
- Control Arm: AREDS2 supplements (SOC)
- Outcomes measured
- Adverse Events Assessment using CTCAE v5.0 — Evaluation in 26 weeks treatment period, and 4 weeks safety follow up peri…; GA lesion size change — From baseline to Week 26 treatment period; Overall retinal sensitivity — From baseline to Week 26 treatment period; BCVA in number of letters — From baseline to Week 26 treatment period, and 4 weeks safety follow up period.; Low luminance visual acuity (LLVA) — From baseline to Week 26 treatment period; Binocular reading speed — From baseline to Week 26 treatment period; Binocular critical print size — From baseline to Week 26 treatment period; NEI-VFQ score — From baseline to Week 26 treatment period; Plasma levels of bioactive lipids — From baseline to Week 26 treatment period; Plasma levels of beclin-1 levels — From baseline to Week 26 treatment period; Complement factor levels — From baseline to Week 26 treatment period
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.